Transcriptional and translational markers of syncytialization and biochemical differentiation are significantly decreased by rotenone. by O’Llenecia S. Walker (8486163)

Detection of the Challenging mutations at 1% VAF and 50 ng DNA input. by Lizhi Yu (12476136)

IC₅₀s data of antimalarials against controls. by Winnie Okore (14139712)

Subjects:

Drugs IC₅₀s data during the study period. by Winnie Okore (14139712)

Subjects:

SNPs IC₅₀s data at codon 876 during the study period. by Winnie Okore (14139712)

Subjects:

Association of polymorphic IC_50s versus wild<i>-</i>type at codon 876 in selected drugs tested. by Winnie Okore (14139712)

Subjects:

Effect of melatonin (50 μM) on the TGF-β1 (10 ng/mL, 72 h)-mediated TGF-β1/Smad pathway and EMT in HBdSMCs. by Yang Zhang (30734)

ROC curve and P-R curve (attack traffic proportion = 50%). by Longyan Ran (18452261)

mGluR5 receptor decreased glycinergic currents. by Zi-Yang Zhang (4988555)

“…(<b>E</b>) The inhibitory effect of CHPG on GlyR-IPSCs was not blocked by intracellularly loaded GDP-β-S (62.3 ± 6.4% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.782, <i>p</i> = 0.032), chelerythrine (60.9 ± 11.3% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.705, <i>p</i> = 0.035), or Ro-32-0432 (69.9 ± 3.2% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 8.495, <i>p</i> < 0.001). (<b>F</b>) Postsynaptic loading of U-0126 or PD98059 prevented CHPG from decreasing glycinergic responses (U-0126, 107.6 ± 10.4% of baseline at 15–20 min post-CHPG, <i>t</i>[8] = 0.997, <i>p</i> = 0.348; PD98059, 93.1 ± 5.0% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 0.883, <i>p</i> = 0.418). …”

Adjustment for the individual conus medullaris (CM) length (60, 50, 40, and 30 mm for the displayed cases). by Silvan Büeler (18389510)

Ce6 decreases the amount of TMV PQS5 upon photo-irradiation. by Congbao Xie (17599247)

Number of samples per site during the study period. by Winnie Okore (14139712)

Subjects:

Performance of selected antimalarials against field isolates during the study period. by Winnie Okore (14139712)

Subjects:

<i>Pfmrp1</i> gene SNPs data during the study period. by Winnie Okore (14139712)

Subjects:

Performance of selected drugs against field isolates during the study period. by Winnie Okore (14139712)

Subjects:

Frequency of SNPs in <i>Pfmrp1</i> gene in field isolates during the study period. by Winnie Okore (14139712)

Subjects:

<i>In vitro</i> 95% CI lower and upper mean susceptibility responses of field isolates to antimalarials. by Winnie Okore (14139712)

Subjects:

<i>In vitro</i> susceptibility responses of field isolates to antimalarials during the study period. by Winnie Okore (14139712)

Subjects:

Primers used for analysis of four SNPs in one gene. by Winnie Okore (14139712)

Subjects:

Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50. by Khamis Mustafa (17941332)

“…<p>Cell lysates were obtained from THP-1 monocytes exposed to reagents as indicated: Lane 1, vehicle; Lane 2, PARP inhibitor olaparib (5 mM, 24 hr); Lane 3, oxLDL (100 mg/mL, 24 hr) or Lane 4, combination of oxLDL and olaparib. …”